[go: up one dir, main page]

JP2004217555A - Polyphenol derived from walnut kernel - Google Patents

Polyphenol derived from walnut kernel Download PDF

Info

Publication number
JP2004217555A
JP2004217555A JP2003005774A JP2003005774A JP2004217555A JP 2004217555 A JP2004217555 A JP 2004217555A JP 2003005774 A JP2003005774 A JP 2003005774A JP 2003005774 A JP2003005774 A JP 2003005774A JP 2004217555 A JP2004217555 A JP 2004217555A
Authority
JP
Japan
Prior art keywords
antioxidant
aromatic
present
granulin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003005774A
Other languages
Japanese (ja)
Other versions
JP2004217555A5 (en
JP4303481B2 (en
Inventor
Toshiyuki Fukuda
寿之 福田
Takashi Yoshida
隆志 吉田
Hideyuki Ito
秀之 伊東
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Orbis Holdings Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Priority to JP2003005774A priority Critical patent/JP4303481B2/en
Publication of JP2004217555A publication Critical patent/JP2004217555A/en
Publication of JP2004217555A5 publication Critical patent/JP2004217555A5/ja
Application granted granted Critical
Publication of JP4303481B2 publication Critical patent/JP4303481B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new antioxidant component suitable for use in antioxidant compositions, specifically foods. <P>SOLUTION: The new antioxidant consists of a new compound represented by the general formula(1)( wherein, R1, R2, R3, R4, R5, R6, R7, R6 and R9 are each H, a 6-15C aromatic group or 6-15C aromatic acyl group, wherein either aromatic or aromatic acyl group may be the same in base as other acyl groups, and the bond indicated by a broken line may be present or absent ), for example, granslin A, granslin B or granslin C. The compound is obtained by extraction and purification of walnut kernels. It is preferable that this compound be incorporated as an antioxidant in ordinary foods, health foods or specific health foods in the form of tablets, granules or capsules intended for health maintenance or health promotion. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は、抗酸化用の組成物に関し、更に詳細には、食品に好適な抗酸化用の組成物に関する。
【0002】
【従来の技術】
酸化は生命活動においては、生命活動の維持に必要なエネルギーを作り出す、重要な化学反応であり、且つ、免疫系において細菌などの侵入非自己生物を攻撃する有用な生体防御手段でもある。しかし、一方、酸化反応、それも生体による制御の効かない酸化反応は生体に大きなダメージを与える。特に、脂質などが酸化されて生じる過酸化物は生体にとって大きな傷害をもたらすし、光老化では過酸化物が大きな要因となっていることが指摘されている。又、炎症においても酸化は大きな役割を果たしており、慢性的な炎症が発ガンの重要因子であることを考えると、酸化は発ガンとも深い関係にあるといえる。即ち、生体において、適切に酸化反応、詳細に言えば、過酸化反応を制御することは、生体の維持と健康の維持にとって大変有用なことであるといえる。この様な目的で、種々の抗酸化剤が使用されており、例えば、この様な抗酸化剤としては、古くはBHT或いはBHAと言った芳香族系の物質が存在し、近年においてはアスコルビン酸、アスコルビン酸リン酸マグネシウム、アスコルビン酸グルコシド等のアスコルビン酸類、トコフェロール類などが存在する。しかしながら、芳香族系の物質については安全性の懸念がぬぐいきれず、アスコルビン酸やその誘導体は、水溶性が高いために生体内での貯留時間に不適切な場合があったり、安定性に問題がある場合があった。(再表平11−59580)トコフェロール類においては、着色や異臭の問題がある場合があり、これらを適度に組み合わせて使用しているのが現状であるといえる。組合せである以上、これらの組合せ素材のみでは対応できない場合があり、すそ野を広げる意味において、新規の抗酸化成分が求められていた。
【0003】
一方、胡桃の抽出物の内、その殻の抽出物中に抗酸化物質が存在することは既に知られているが、(特開2000−72686)仁について、抗酸化物質を含んでいる報告はない。又、後記グランスリンA、B及びCは何れも文献未記載の新規物質であり、従って、この物質が抗酸化作用を有していることも全く知られていない。
【0004】
【発明が解決しようとする課題】
本発明は、この様な状況下為されたものであり、新規の抗酸化成分を提供することを課題とする。
【0005】
【課題の解決手段】
この様な状況に鑑みて、本発明者らは、胡桃仁の脱脂物が優れた抗酸化作用を有することを見出し、胡桃仁の脱脂物について、抗酸化作用を指標に分画、スクリーニングを続けた結果、グランスリンA、グランスリンB或いはグランスリンCと言った一般式(1)に表される新規化合物又はその塩がその有効成分であることを見出し、発明を完成させた。即ち、本発明は、以下に示す技術に関するものである。
(1)下記一般式(1)に表される化合物又はその塩。
【0006】
【化5】

Figure 2004217555
一般式(1)
(但し、式中R1、R2、R3、R4、R5、R6、R7、R8、R9はそれぞれ独立に水素原子、炭素数6〜15の芳香族基又は炭素数6〜15の芳香族のアシル基を表し、且つ、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていてもよく、破線の結合はあってもなくても良い。)
【0007】
(2)一般式(1)に表される化合物が、グランスリンA、グランスリンB又はグランスリンCであることを特徴とする、(1)に記載の化合物又はその塩。
【0008】
【化6】
Figure 2004217555
グランスリンA
【0009】
【化7】
Figure 2004217555
グランスリンB
【0010】
【化8】
Figure 2004217555
グランスリンC
【0011】
(3)(1)又は(2)に記載の化合物からなる抗酸化剤。
(4)(3)に記載の抗酸化剤を0.1〜30重量%含有する、活性酸素消去用の経口投与組成物。
(5)食品であることを特徴とする、(4)に記載の経口投与組成物。
【0012】
【発明の実施の形態】
(1)本発明の化合物
本発明の化合物は、一般式(1)に表される構造を有する。かかる化合物は、フェノール性の水酸基を有している為、アルカリなどともに塩の形にして使用することも可能である。かかる塩としては、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩、カルシウム、マグネシウム等のアルカリ土類金属塩、アンモニウム塩、トリエタノールアミン塩、トリエチルアミン塩等の有機アミン塩類、リジン塩、アルギニン塩等の塩基性アミノ酸塩等が好ましく例示できる。一般式(1)に於いて、R1、R2、R3、R4、R5、R6、R7、R8、R9はそれぞれ独立に水素原子、フェニル基、ビフェニル基などの炭素数6〜15の芳香族基又はフェニルカルボニル基、ビフェニルカルボニル基などの炭素数6〜15の芳香族のアシル基を表し、且つ、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていてもよく、破線の結合はあってもなくても良い。ここで、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていても良いとは、例えば、フタロイル基などのように二つ以上のカルボニル基を有する置換基のカルボニル基が糖鎖上の二つ以上の水酸基と反応してジエステルなどを形成するような状況を意味する。即ち、アシル基のカルボニル基以外を共有する場合、アシル基のカルボニル基以外の部分とエーテルを形成する芳香族基が共有されている場合、或いは、レゾルシン残基のように、二つのエーテルの芳香族基が共有されている場合などである。本発明の化合物として、好ましいものは、グランスリンA、グランスリンB及びグランスリンCである。これらの化合物は、胡桃の仁を脱脂した後、極性溶媒で抽出し、液液抽出、カラムクロマトグラフィーなどで精製することにより、製造することが出来る。脱脂はノルマルヘキサンなどの非極性溶剤を使用して抽出することによって行うことが出来る。ジエチルエーテル、イソプロピルエーテル、テトラヒドロフランなどのエーテル類、塩化メチレン、クロロホルムなどのハロゲン化炭化水素類、酢酸エチル、蟻酸メチルなどのエステル類、アセトンやメチルエチルケトン等のケトン類、アセトニトリルなどのニトリル類、1,3−ブタンジオール、エタノール、イソプロピルアルコールなどのアルコール類、水などが好ましく例示できる。これらの内では、アルコール及び/又は水が特に好ましい。抽出は、植物体に対して1〜10重量倍の溶剤を加え、室温であれば数日間、沸点付近の温度であれば数時間浸漬すればよい。抽出後は、必要に応じて、減圧濃縮などして溶剤を除去することが好ましい。又、液液抽出は、ノルマルブタノールと水の溶媒系が好ましく例示できるし、カラムクロマトグラフィーとしては、担体をシリカゲルとして、溶出溶媒をクロロホルム−メタノール系で行うもの、イオン交換樹脂を担体として、水−メタノール系溶媒を溶出溶媒とするものなどが好ましく例示できる。
【0013】
(2)本発明の抗酸化剤
本発明の抗酸化剤は、前記本発明の化合物及び/又はその塩からなることを特徴とする。本発明の化合物は、優れた抗酸化作用を有する為、経口投与組成物に含有させることにより、経口投与組成物中の酸化に弱い成分を酸化から保護することが出来るし、又、消化管より吸収されて体内に分布し、生体成分或いは生体構成成分が酸化するのを防ぐ作用を発揮する。特に、近年の生体酸化関連の研究によれば、生体構成成分の酸化は老化の重要な因子となっており、これを防ぐことにより老化を防止できる蓋然性が高い。従って、本発明の抗酸化剤は、老化防止の目的で使用することが出来る。この様な効果を奏する為には、本発明の抗酸化剤は、組成物中に0.1〜30重量%含有することが好ましく、更に好ましくは、0.2〜10重量%である。又、本発明の抗酸化剤は、本発明の経口投与組成物のみならず、抗酸化剤を用いる他の製剤に含有させることも出来る。かかる製剤としては、皮膚外用医薬や化粧料などの皮膚外用剤が好適に例示できる。この様な製剤に於ける、本発明の抗酸化剤の好適な含有量は、0.01〜10重量%であり、更に好ましくは0.05〜1重量%である。
【0014】
(3)本発明の経口投与組成物
本発明の経口投与組成物は、上記本発明の抗酸化剤を含有することを特徴とする。経口投与組成物としては、経口で投与されるものであれば特段の限定はないが、食品が特に好適に例示できる。食品としては、飴、ガム、焼き菓子などの菓子やソーセージ、ハム、はんぺん、インスタントラーメン等の惣菜などの通常の食品や健康維持や健康促進を目的とする、錠剤や顆粒剤、カプセル剤形式の健康食品或いは特定保険用食品などが好ましく例示できる。通常の食品においては、本発明の抗酸化剤は、酸化から食品を守る目的で使用できる。又、健康維持や健康促進を目的とする、健康食品或いは特定保険用食品などでは、体内に於ける過酸化物の発生や炎症を防ぐ作用を発揮し、老化、発ガンなどを抑制する作用を発揮する。又、アスコルビン酸類やトコフェロール類など酸化を受けやすい有効成分の安定性を高める作用を発揮する。本発明の食品においては、必須成分の抗酸化剤以外に食品で通常使用される任意成分を含有することができる。かかる任意の成分としては、例えば、賦形剤、結合剤、矯味剤、矯臭剤、滑沢剤、被覆剤、増粘剤、乳化剤、分散剤、着色剤、油脂等が好ましく例示できる。これら必須の成分と任意の成分とを常法に従って処理することにより、本発明の食品は製造できる。
【0015】
【実施例】
以下に、実施例を挙げて、本発明について更に詳細に説明を加えるが、本発明が、かかる実施例にのみ限定されないことは言うまでもない。
【0016】
<実施例1>
カシグルミの可食部10kgを圧搾用の型にいれ、35℃条件下、100Kg/cm2で4時間加圧して、油脂分を除去した。圧搾した残りを50%エタノール水溶液で抽出し、濾過して不溶物を除去した後、減圧濃縮して残査310g(本発明の抗酸化用の組成物1)を得た。これを全て、ダイアイオンHP−20(三菱化成製)カラムクロマトグラフィー(溶出溶媒;水:メタノール=100:0〜0:100)およびODSカラムを装着した分取高速液体クロマトグラフィーで精製し、グランスリンAを13mg、グランスリンBを28mg及びグランスリンCを9mg得た。各化合物の物性値は以下の通り。
(グランスリンA)
オフホワイトのアモルファス粉末; [α]D23 −11°(c 0.3, MeOH); ネガティブFABMS m/z 1103 [M−H]−; CD (MeOH) [θ] (nm) +2.3 x 105 (238), −6.9 x 104 (263), +6.0 x 103 (282). 1H NMR (500 MHz, アセトン−d6+重水) δ 7.20 (2H, s), 6.93 (1H, s), 6.62 (1H, s), 6.57 (1H, s), 6.48 (1H, s), 6.38 (1H, s), グルコースプロトンδ6.24 (1H, d, J=8.5 Hz), 5.22 (1H, t, J=9 Hz), 5.48 (1H, dd, J=9, 10 Hz), 5.24 (1H, t, J=10 Hz), 4.54 (1H, dd, J=6.5, 9 Hz), 5.37 (1H, dd, J=6.5, 13 Hz), 3.92 (1H, d, J=13 Hz); 13C NMR(126 MHz, アセトン−d6+重水)δ63.3, 69.1, 73.4, 76.0, 77.0, 92.3, 107.1, 107.3, 107.7, 107.9, 108.3, 110.2 (2C), 114.2 (2C), 115.1, 116.9, 117.5, 119.8, 125.0, 126.0, 126.3, 131.9, 136.1, 136.6, 137.2, 137.4, 139.0,139.4, 139.6, 140.0, 142.4, 144.49, 144.53, 144.9, 145.1, 145.2 (2C), 146.3 (2C), 150.0 (2C), 165.1, 168.11, 168.15, 168.8, 169.4, 172.2.
(グランスリンB)
黄色みがかったアモルファスの粉末; [α]D23 +90°(c 0.1, MeOH); ネガティブFABMS m/: 905 [M−H]−; CD (MeOH) [θ] (nm) +1.9 x 105 (238), −5.6 x104 (266), +1.7 x 104 (285); 1H NMR (500 MHz, アセトン−d6+重水) δ 6.73, 6.71 (1H, in total, each s), 6.60, 6.55 (1H, in total, each s), 6.614, 6.618 (1H, in total, each s), 6.373, 6.368 (1H, in total, each s), 5,947, 5.941 (1H, in total, each s), グルコースプロトンδ5.46 (0.5 H, d,J=4 Hz), 5.08 (0.5 H, dd, J=4, 10 Hz), 5.49 (0.5 H, t, J=10 Hz), 5.12 (0.5 H, t, J=10 Hz), 4.62 (0.5 H, ddd, J=1.5, 6.5, 10 Hz), 5.19 (0.5 H, dd, J=6.5, 13 Hz), 3.83 (0.5 H, dd, J=1.5, 13 Hz)(αアノマー); 5.06 (0.5 H, d, J=8 Hz), 4.87 (0.5 H, dd, J=8, 9 Hz), 5.25 (0.5 H, dd, J=9, 10 Hz), 5.11 (0.5 H, t, J=10 Hz), 4.23 (0.5 H, ddd, J=1, 6.5, 10 Hz), 5.21 (0.5 H, dd, J=6.5, 13 Hz), 3.90 (0.5 H, dd, J=1, 13 Hz)(βアノマー); 13C NMR (126 MHz, アセトン−d6+重水)δ64.1, 64.2, 67.3, 69.7, 70.1, 72.3, 75.6, 75.7, 77.5, 78.3, 91.7, 95.2 (1C), 95.5, 106.77, 106.83, 107.2, 107.30, 107.34, 107.7, 110.4 (1C), 113.9 (1C), 114.3, 114.4, 114.9, 115.0 115.7 (1C), 124.7 (1C), 125.37, 125.42, 126.5 (1C), 126.6, 126.7, 130.2, 130.3, 130.5 (1C), 133.03, 133.05, 135.3 (1C), 135.5 (1C), 136.0, 136.1, 136.2 (1C), 136.4 (1C), 142.1 (1C), 142.2 (1C), 144.3 (1C), 144,4 (1C), 145.0 (1C), 145.13, 145.19, 145.27, 145.32, 145.5 (1C), 145.6 (1C), 167.6, 167.7, 168.1 (1C), 168.9, 169.0, 169.5, 169.6.
(グランスリンC)
黄色みがかったアモルファスの粉末; [α]D23 +79°(c 0.1, MeOH); ネガティブFABMS m/z 933 [M−H]−; CD (MeOH) [θ] (nm) +1.6 x 105 (228), −3.4 x104 (252), +2.8 x 104 (287); 1H NMR (500 MHz, アセトン−d6+重水)δ6.93 (1H, s), 6.89 (1H, s), 6.76 (1H, s), 6.43 (1H, s), グルコースプロトンδ5.65 (1H, d, J=5 Hz), 4.68 (1H, dd, J=2, 5 Hz), 5.49 (1H, t, J=2.5 Hz), 5.12 (1H, dd, J=3, 8 Hz), 4.17 (1H, dd, J=2, 8 Hz), 4.62 (1H, dd, J=3,12 Hz), 3.92 (1H, d, J=12 Hz); 13C NMR (126 MHz, アセトン−d6+重水)δ67.7, 68.3, 68.9, 70.8, 77.0, 77.2, 105.2, 107.5, 109.8, 111.5, 112.7, 114.2, 116.1, 116.5, 116.8, 120.3, 120.5, 124.7, 127.7, 133.4, 135.0, 136.3, 136.6, 138.6, 140.5, 142.4, 143.68, 143.74, 143.9, 144.1, 145.27, 145.33, 145.7, 145.8, 146.3, 148.4, 163.3, 164.9, 168.3, 168.6, 170.3.
【0017】
<実施例2>
キサンチン−キサンチンオキシダーゼ(XOD)系により活性酸素のひとつであるスーパーオキシドアニオン(O2−)を発生させ、発生したO2−の生成率を亜硝酸法により測定し、この値をキサンチンオキシダーゼ阻害活性値で補正して抗酸化作用値を求めた。実施例1で得られた本発明の抗酸化剤を50μg/mlの割合で含有する抗酸化組成物水溶液0.1mlを、65mMリン酸2水素カリウム、35mMホウ酸ナトリウム、0.5mMEDTA2ナトリウム水溶液(以下、緩衝液Aという)0.2ml、0.5mMキサンチン溶液0.2ml、10mMヒドロキシルアミン塩酸塩水溶液0.1ml、純水0.2mlの混合液に、加えてよく撹拌し試験液とした。同様にして、抗酸化用の組成物の代わりに純水0.1mlを用いたコントロールの溶液を作製した上記各試験液及びコントロール溶液に、キサンチンオキシダーゼを1μl/ml濃度で含有する緩衝液Aを0.2ml加えて撹拌した後、37℃で30分インキュベーションした。ブランクとして、上記と同様に調整された試験液及びコントロール溶液に、キサンチンオキシダーゼを含まない緩衝液Aを0.2ml加え、上記と同様に処理した溶液を用意した。このようにして得られた各溶液のそれぞれに、30μMN−1−ナフチルエチレンジアミン塩酸塩、3mMスルファニル酸、25%氷酢酸混液2mlを加え、30分間室温で放置した後、各溶液について、550nmでの吸光度で活性酸素の発生量を、295nmの吸光度で尿酸の発生量を測定した。得られた値を用いて、以下の式に基づき、抗酸化作用値をEC50として算出した。この結果を表1に示す。これより、本発明の化合物であるグランスリンA、B及びCは優れた抗酸化活性を有していることがわかる。尚、この時、アスコルビン酸のEC50値は、34.6 mMであった。
<抗酸化活性を求める式>
活性酸素発生率=[(A550−3−A550−4)/(A550−1−A550−2)]×100
尿酸生成率=[(A295−3−A295−4)/(A295−1−A295−2)]×100
抗酸化活性=100−(活性酸素発生率/尿酸生成率)×100
【0018】
【表1】
Figure 2004217555
【0019】
<実施例3>
下記に示す処方に従って、本発明の食品である錠剤を作成した。即ち、処方成分をフローコーターに仕込み、20重量部の水を噴霧しながら、流動層造粒を行い、3時間40℃で送風乾燥し、顆粒を得た。これを打錠して錠剤を得た。これらの錠剤を無色透明なガラス瓶に詰め、室内で電灯下1週間の露光試験を行った。比較例1として、抗酸化剤を結晶セルロースに置換したものを、比較例2として、抗酸化剤をBHTに置換したものも作成した。対照として、これらのサンプルと同じものを遮光下にも別途保存した。露光試験後、対照と比較して退色の程度を次の基準に従って判定した。即ち、スコア5:対照とほぼ同じ色、スコア4:対照よりやや黄味が薄い、スコア3:対照に比して黄味の薄さが明白に感じられる、スコア2:かなり白い、スコア1:殆ど白であった。結果を表3に示す。これより、本発明の抗酸化用の組成物は酸化による退色を防ぐ作用に優れることがわかる。
結晶セルロース 40重量部
乳糖 20重量部
表2に記載の抗酸化剤 30重量部
リボフラビン 1重量部
ヒドロキシプロピルメチルセルロース 8重量部
ステアリン酸マグネシウム 1重量部
【0020】
【表2】
Figure 2004217555
【0021】
<実施例6>
実施例4の食品を用いて、飲用試験を行った。即ち、3月〜4月の花粉症の季節に花粉症に悩むパネラー1群20名に実施例4の食品(本発明群)又は比較例1の食品(対照群)を1日2回500mgずつ1ヶ月飲用してもらった。その後、その年の花粉症の症状の出方について、(1)いつもの年より良い(2)いつもの年と同じ程度(3)いつもの年より悪いの3者択一の選択で評価してもらった。結果を表3に出現例数として示す。これより、本発明の食品飲用群はいつもの年より花粉症が軽度であったことがわかる。これは、本発明の抗酸化用の組成物により、炎症が抑えられているためと思われる。
【0022】
【表3】
Figure 2004217555
【0023】
【発明の効果】
本発明によれば、新規の抗酸化成分を提供することができる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an antioxidant composition, and more particularly to an antioxidant composition suitable for food.
[0002]
[Prior art]
Oxidation is a vital chemical reaction that creates the energy needed to sustain life activity in life activity, and is also a useful biological defense tool that attacks invading non-self organisms such as bacteria in the immune system. However, on the other hand, an oxidation reaction, which is not controlled by the living body, causes great damage to the living body. In particular, it has been pointed out that peroxides generated by oxidation of lipids and the like cause serious damage to living organisms, and that peroxide is a major factor in photoaging. Oxidation also plays a major role in inflammation, and considering that chronic inflammation is an important factor in carcinogenesis, it can be said that oxidation is closely related to carcinogenesis. That is, it can be said that appropriately controlling an oxidation reaction, specifically, a peroxidation reaction, in a living body is very useful for maintaining the living body and maintaining health. For this purpose, various antioxidants have been used. For example, as such antioxidants, aromatic substances such as BHT or BHA existed in the old days, and in recent years, ascorbic acid has been used. , Ascorbic acids such as magnesium phosphate ascorbate and glucoside ascorbate, and tocopherols. However, safety concerns remain with regard to aromatic substances, and ascorbic acid and its derivatives may be inappropriate for storage time in vivo due to their high water solubility, or have problems with stability. There was a case. (Reappearance 11-59580) Tocopherols may have a problem of coloring or offensive odor, and it can be said that at present, these are used in an appropriate combination. As long as it is a combination, there is a case where it is not possible to cope with these combined materials alone, and a new antioxidant component has been demanded from the viewpoint of expanding the field.
[0003]
On the other hand, among the extracts of walnut, it is already known that an antioxidant is present in the extract of the shell, but (Japanese Patent Application Laid-Open No. 2000-72686) has reported that Jin contains an antioxidant. Absent. In addition, all of Gransulin A, B, and C described below are novel substances not described in the literature, and thus it is not known at all that this substance has an antioxidant effect.
[0004]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and it is an object of the present invention to provide a novel antioxidant component.
[0005]
[Means for solving the problem]
In view of such a situation, the present inventors have found that defatted walnuts have an excellent antioxidant effect, and fractionated and screened the defatted walnuts using the antioxidant activity as an index. As a result, the present inventors have found that a novel compound represented by the general formula (1) such as granulin A, granulin B or granulin C or a salt thereof is an active ingredient thereof, and completed the invention. That is, the present invention relates to the following technology.
(1) A compound represented by the following general formula (1) or a salt thereof.
[0006]
Embedded image
Figure 2004217555
General formula (1)
(Wherein, R1, R2, R3, R4, R5, R6, R7, R8, and R9 each independently represent a hydrogen atom, an aromatic group having 6 to 15 carbon atoms, or an aromatic acyl group having 6 to 15 carbon atoms) , And any of the aromatic groups and aromatic acyl groups may have the same substrate as other acyl groups, and may or may not have a bond indicated by a broken line.)
[0007]
(2) The compound according to (1) or a salt thereof, wherein the compound represented by the general formula (1) is granthrin A, granthrin B or granthrin C.
[0008]
Embedded image
Figure 2004217555
Granulin A
[0009]
Embedded image
Figure 2004217555
Granulin B
[0010]
Embedded image
Figure 2004217555
Granulin C
[0011]
(3) An antioxidant comprising the compound according to (1) or (2).
(4) A composition for oral administration for eliminating active oxygen, comprising the antioxidant according to (3) in an amount of 0.1 to 30% by weight.
(5) The composition for oral administration according to (4), which is a food.
[0012]
BEST MODE FOR CARRYING OUT THE INVENTION
(1) Compound of the Present Invention The compound of the present invention has a structure represented by the general formula (1). Since such a compound has a phenolic hydroxyl group, it can be used in the form of a salt together with an alkali or the like. Examples of such salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as calcium and magnesium, ammonium salts, organic amine salts such as triethanolamine salts and triethylamine salts, lysine salts, and arginine salts. And the like can be preferably exemplified. In the general formula (1), R1, R2, R3, R4, R5, R6, R7, R8 and R9 each independently represent a hydrogen atom, an aromatic group having 6 to 15 carbon atoms such as a phenyl group, a biphenyl group or the like. Represents an aromatic acyl group having 6 to 15 carbon atoms such as a phenylcarbonyl group and a biphenylcarbonyl group, and any of the aromatic groups and aromatic acyl groups may have the same base as another acyl group. The connection of the broken lines may or may not be present. Here, any aromatic group or aromatic acyl group may have the same base as another acyl group, for example, a substituent having two or more carbonyl groups such as a phthaloyl group. It means a situation in which a carbonyl group reacts with two or more hydroxyl groups on a sugar chain to form a diester or the like. That is, when a group other than the carbonyl group of the acyl group is shared, when an aromatic group forming an ether is shared with a portion other than the carbonyl group of the acyl group, or when two aromatic groups such as a resorcinol residue are present. For example, when a group is shared. Preferred as the compound of the present invention are Glansulin A, Granulin B and Granulin C. These compounds can be produced by defatting walnut kernels, extracting them with a polar solvent, and purifying them by liquid-liquid extraction, column chromatography or the like. Degreasing can be performed by extraction using a non-polar solvent such as normal hexane. Ethers such as diethyl ether, isopropyl ether and tetrahydrofuran; halogenated hydrocarbons such as methylene chloride and chloroform; esters such as ethyl acetate and methyl formate; ketones such as acetone and methyl ethyl ketone; nitriles such as acetonitrile; Preferred examples include alcohols such as 3-butanediol, ethanol, and isopropyl alcohol, and water. Of these, alcohol and / or water are particularly preferred. Extraction may be performed by adding a solvent in an amount of 1 to 10 times the weight of the plant and immersing it for several days at room temperature or for several hours at a temperature near the boiling point. After the extraction, if necessary, it is preferable to remove the solvent by concentration under reduced pressure or the like. The liquid-liquid extraction can be preferably exemplified by a solvent system of normal butanol and water, and the column chromatography is performed by using silica gel as a carrier, a chloroform-methanol system as an elution solvent, and an ion exchange resin as a carrier. Preferred examples include those using a methanol-based solvent as an elution solvent.
[0013]
(2) Antioxidant of the present invention The antioxidant of the present invention comprises the compound of the present invention and / or a salt thereof. Since the compound of the present invention has an excellent antioxidant effect, by containing it in the composition for oral administration, it is possible to protect the oxidatively weak component in the composition for oral administration from oxidation, It is absorbed and distributed in the body and exerts an effect of preventing oxidation of biological components or biological components. In particular, according to recent studies on biological oxidation, oxidation of biological constituents is an important factor in aging, and it is highly probable that aging can be prevented by preventing this. Therefore, the antioxidant of the present invention can be used for the purpose of preventing aging. In order to exhibit such an effect, the antioxidant of the present invention is preferably contained in the composition in an amount of 0.1 to 30% by weight, more preferably 0.2 to 10% by weight. Further, the antioxidant of the present invention can be contained not only in the composition for oral administration of the present invention but also in other preparations using the antioxidant. As such a preparation, a skin external preparation such as a skin external medicine or a cosmetic can be suitably exemplified. In such a preparation, the preferred content of the antioxidant of the present invention is 0.01 to 10% by weight, more preferably 0.05 to 1% by weight.
[0014]
(3) The composition for oral administration of the present invention The composition for oral administration of the present invention is characterized by containing the above-mentioned antioxidant of the present invention. The composition for oral administration is not particularly limited as long as it can be administered orally, but a food can be particularly preferably exemplified. Foods include candy, gum, baked confectionery and other confectionery and sausages, ham, hampan, instant noodles and other prepared foods, and tablets, granules and capsules for the purpose of maintaining and promoting health. Preferred examples include health foods and foods for specific insurance. In ordinary foods, the antioxidants of the present invention can be used to protect foods from oxidation. In the case of health foods or foods for specified insurance purposes for the purpose of maintaining and promoting health, it has the effect of preventing the generation of peroxides and inflammation in the body and the effect of suppressing aging and carcinogenesis. Demonstrate. Also, it exerts an effect of increasing the stability of active ingredients which are easily oxidized such as ascorbic acids and tocopherols. The food of the present invention may contain optional components usually used in foods in addition to the essential antioxidant. Preferred examples of such optional components include excipients, binders, flavoring agents, flavoring agents, lubricants, coating agents, thickeners, emulsifiers, dispersants, coloring agents, fats, and the like. The food of the present invention can be produced by treating these essential components and optional components in a conventional manner.
[0015]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples, but it is needless to say that the present invention is not limited to only these Examples.
[0016]
<Example 1>
10 kg of the edible portion of the red walnut was put into a pressing mold and pressed at 100 kg / cm 2 for 4 hours at 35 ° C. to remove oils and fats. The compressed residue was extracted with a 50% aqueous ethanol solution, filtered to remove insolubles, and then concentrated under reduced pressure to obtain 310 g of a residue (composition 1 for antioxidation of the present invention). All of this was purified by Diaion HP-20 (manufactured by Mitsubishi Kasei) column chromatography (elution solvent; water: methanol = 100: 0 to 0: 100) and preparative high-performance liquid chromatography equipped with an ODS column. 13 mg of phosphorus A, 28 mg of glansulin B and 9 mg of glansulin C were obtained. The physical properties of each compound are as follows.
(Gran Surin A)
Off-white amorphous powder; [α] D23 −11 ° (c 0.3, MeOH); Negative FABMS m / z 1103 [MH] −; CD (MeOH) [θ] (nm) + 2.3 × 105 (238), -6.9 x 104 (263), +6.0 x 103 (282). 1H NMR (500 MHz, acetone-d6 + heavy water) δ 7.20 (2H, s), 6.93 (1H, s), 6.62 (1H, s), 6.57 (1H, s), 6. 48 (1H, s), 6.38 (1H, s), glucose proton δ 6.24 (1H, d, J = 8.5 Hz), 5.22 (1H, t, J = 9 Hz), 5. 48 (1H, dd, J = 9, 10 Hz), 5.24 (1H, t, J = 10 Hz), 4.54 (1H, dd, J = 6.5, 9 Hz), 5.37 ( 1H, dd, J = 6.5, 13 Hz), 3.92 (1H, d, J = 13 Hz); 13C NMR (126 MHz, acetone-d6 + heavy water) δ 63.3, 69.1, 73.4. , 76.0, 77.0, 92.3, 107.1, 107.3, 107 .7, 107.9, 108.3, 110.2 (2C), 114.2 (2C), 115.1, 116.9, 117.5, 119.8, 125.0, 126.0, 126 1.3, 131.9, 136.1, 136.6, 137.2, 137.4, 139.0, 139.4, 139.6, 140.0, 142.4, 144.49, 144.53. , 144.9, 145.1, 145.2 (2C), 146.3 (2C), 150.0 (2C), 165.1, 168.11, 168.15, 168.8, 169.4, 172.2.
(Gran Surin B)
[Α] D23 + 90 ° (c 0.1, MeOH); Negative FABMS m /: 905 [MH] −; CD (MeOH) [θ] (nm) +1.9 x 105 (238), −5.6 × 104 (266), + 1.7 × 104 (285); 1H NMR (500 MHz, acetone-d6 + heavy water) δ 6.73, 6.71 (1H, in total, each s) ), 6.60, 6.55 (1H, in total, each s), 6.614, 6.618 (1H, total, each s), 6.373, 6.368 (1H, in total, each). s), 5,947, 5.941 (1H, in total, each s), glucose proton δ 5.46 (0.5 H, d, = 4 Hz), 5.08 (0.5 H, dd, J = 4, 10 Hz), 5.49 (0.5 H, t, J = 10 Hz), 5.12 (0.5 H, t, J = 10 Hz), 4.62 (0.5 H, ddd, J = 1.5, 6.5, 10 Hz), 5.19 (0.5 H, dd, J = 6.5, 13 Hz), 3.83 (0.5 H, dd, J = 1.5, 13 Hz) (α anomer); 5.06 (0.5 H, d, J = 8 Hz), 4.87 ( 0.5H, dd, J = 8, 9 Hz), 5.25 (0.5 H, dd, J = 9, 10 Hz), 5.11 (0.5 H, t, J = 10 Hz) , 4.23 (0.5 H, ddd, J = 1, 6.5, 10 Hz), 5.21 (0.5 H, dd, J = 6.5, 13 Hz), 3.90 (0 .5 H, d d, J = 1, 13 Hz) (β anomer); 13 C NMR (126 MHz, acetone-d6 + deuterated water) δ 64.1, 64.2, 67.3, 69.7, 70.1, 72.3, 75 .6, 75.7, 77.5, 78.3, 91.7, 95.2 (1C), 95.5, 106.77, 106.83, 107.2, 107.30, 107.34, 107.7, 110.4 (1C), 113.9 (1C), 114.3, 114.4, 114.9, 115.0 115.7 (1C), 124.7 (1C), 125.37. , 125.42, 126.5 (1C), 126.6, 126.7, 130.2, 130.3, 130.5 (1C), 133.03, 133.05, 135.3 (1C), 135.5 (1C), 136.0, 136.1, 136.2 (1C), 136.4 (1C), 142.1 (1C), 142.2 (1C), 144.3 (1C), 1444 (1C), 145.0 ( 1C), 145.13, 145.19, 145.27, 145.32, 145.5 (1C), 145.6 (1C), 167.6, 167.7, 168.1 (1C), 168. 9, 169.0, 169.5, 169.6.
(Gran Surin C)
[Α] D23 + 79 ° (c 0.1, MeOH); Negative FABMS m / z 933 [MH]-; CD (MeOH) [θ] (nm) +1.6 x 105 (228), -3.4 x 104 (252), +2.8 x 104 (287); 1H NMR (500 MHz, acetone-d6 + heavy water) δ 6.93 (1H, s), 6.89 (1H, s) ), 6.76 (1H, s), 6.43 (1H, s), glucose proton δ 5.65 (1H, d, J = 5 Hz), 4.68 (1H, dd, J = 2, 5 Hz) ), 5.49 (1H, t, J = 2.5 Hz), 5.12 (1H, dd, J = 3, 8 Hz), 4.17 (1H, dd, J = 2, 8 Hz), 4.62 (1H, dd, J = 3,12 Hz), 3.92 (1H, d, J = 12 Hz); 13C NMR (126 MHz, acetone-d6 + heavy water) [delta] 67.7, 68.3, 68.9, 70.8, 77.0, 77. 2, 105.2, 107.5, 109.8, 111.5, 112.7, 114.2, 116.1, 116.5, 116.8, 120.3, 120.5, 124.7, 127.7, 133.4, 135.0, 136.3, 136.6, 138.6, 140.5, 142.4, 143.68, 143.74, 143.9, 144.1, 145. 27, 145.33, 145.7, 145.8, 146.3, 148.4, 163.3, 164.9, 168.3, 168.6, 170.3.
[0017]
<Example 2>
A superoxide anion (O2-), which is one of the active oxygens, is generated by a xanthine-xanthine oxidase (XOD) system, and the generation rate of the generated O2- is measured by a nitrous acid method. After correction, the antioxidant action value was determined. 0.1 ml of an antioxidant composition aqueous solution containing the antioxidant of the present invention obtained in Example 1 at a rate of 50 μg / ml was added to a 65 mM potassium dihydrogen phosphate, 35 mM sodium borate, 0.5 mM EDTA disodium aqueous solution ( The mixture was added to a mixed solution of 0.2 ml of a buffer solution A, 0.2 ml of a 0.5 mM xanthine solution, 0.1 ml of a 10 mM aqueous solution of hydroxylamine hydrochloride, and 0.2 ml of pure water, and stirred well to prepare a test solution. Similarly, a buffer solution containing xanthine oxidase at a concentration of 1 μl / ml was added to each of the above test solutions and control solutions prepared as control solutions using 0.1 ml of pure water instead of the antioxidant composition. After adding 0.2 ml and stirring, the mixture was incubated at 37 ° C. for 30 minutes. As a blank, 0.2 ml of buffer A containing no xanthine oxidase was added to the test solution and control solution prepared in the same manner as above, and a solution treated in the same manner as above was prepared. To each of the thus obtained solutions, 2 ml of a mixture of 30 μM N-1-naphthylethylenediamine hydrochloride, 3 mM sulfanilic acid, and 25% glacial acetic acid was added, and the mixture was allowed to stand at room temperature for 30 minutes. The amount of active oxygen generated was measured by absorbance, and the amount of uric acid was measured by absorbance at 295 nm. Using the obtained value, the antioxidant action value was calculated as EC50 based on the following equation. Table 1 shows the results. This shows that the compounds of the present invention, granthulins A, B and C, have excellent antioxidant activity. At this time, the EC50 value of ascorbic acid was 34.6 mM.
<Equation for determining antioxidant activity>
Active oxygen generation rate = [(A550-3-A550-4) / (A550-1-A550-2)] × 100
Uric acid production rate = [(A295-3-A295-4) / (A295-1-A295-2)] × 100
Antioxidant activity = 100− (active oxygen generation rate / uric acid generation rate) × 100
[0018]
[Table 1]
Figure 2004217555
[0019]
<Example 3>
According to the following prescription, tablets as foods of the present invention were prepared. That is, the prescription components were charged into a flow coater, fluidized-bed granulation was performed while spraying 20 parts by weight of water, and blast-dried at 40 ° C. for 3 hours to obtain granules. This was tableted to obtain a tablet. These tablets were packed in a colorless and transparent glass bottle, and subjected to an exposure test for one week under an electric lamp indoors. As Comparative Example 1, an antioxidant was replaced with crystalline cellulose, and as Comparative Example 2, an antioxidant was replaced with BHT. As a control, the same samples were separately stored under light shielding. After the exposure test, the degree of fading as compared with the control was determined according to the following criteria. That is, score 5: almost the same color as the control, score 4: slightly less yellowish than the control, score 3: light yellowishness is clearly felt compared to the control, score 2: fairly white, score 1: It was almost white. Table 3 shows the results. This indicates that the antioxidant composition of the present invention is excellent in preventing discoloration due to oxidation.
Crystalline cellulose 40 parts by weight Lactose 20 parts by weight Antioxidant described in Table 2 30 parts by weight Riboflavin 1 part by weight Hydroxypropyl methylcellulose 8 parts by weight Magnesium stearate 1 part by weight
[Table 2]
Figure 2004217555
[0021]
<Example 6>
A drinking test was performed using the food of Example 4. That is, the food of Example 4 (the present invention group) or the food of Comparative Example 1 (the control group) was given at a dose of 500 mg twice a day to a group of 20 panelists suffering from hay fever during the season of hay fever from March to April. We had you drink for one month. After that, the way of appearance of the hay fever symptoms of that year was evaluated by three alternatives: (1) Better than usual year (2) Same degree as usual year (3) Worse than usual year received. The results are shown in Table 3 as the number of appearance cases. This indicates that the food and drink group of the present invention had milder hay fever than usual. This is presumably because inflammation was suppressed by the antioxidant composition of the present invention.
[0022]
[Table 3]
Figure 2004217555
[0023]
【The invention's effect】
According to the present invention, a novel antioxidant component can be provided.

Claims (5)

下記一般式(1)に表される化合物又はその塩。
Figure 2004217555
一般式(1)
(但し、式中R1、R2、R3、R4、R5、R6、R7、R8、R9はそれぞれ独立に水素原子、炭素数6〜15の芳香族基又は炭素数6〜15の芳香族のアシル基を表し、且つ、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていてもよく、破線の結合はあってもなくても良い。)
A compound represented by the following general formula (1) or a salt thereof.
Figure 2004217555
General formula (1)
(Wherein, R1, R2, R3, R4, R5, R6, R7, R8, and R9 each independently represent a hydrogen atom, an aromatic group having 6 to 15 carbon atoms, or an aromatic acyl group having 6 to 15 carbon atoms) , And any of the aromatic groups and aromatic acyl groups may have the same substrate as other acyl groups, and may or may not have a bond indicated by a broken line.)
一般式(1)に表される化合物が、グランスリンA、グランスリンB又はグランスリンCであることを特徴とする、請求項1に記載の化合物又はその塩。
Figure 2004217555
グランスリンA
Figure 2004217555
グランスリンB
Figure 2004217555
グランスリンC
The compound according to claim 1, wherein the compound represented by the general formula (1) is granulin A, granulin B or granulin C, or a salt thereof.
Figure 2004217555
Granulin A
Figure 2004217555
Granulin B
Figure 2004217555
Granulin C
請求項1又は2に記載の化合物からなる抗酸化剤。An antioxidant comprising the compound according to claim 1. 請求項3に記載の抗酸化剤を0.1〜30重量%含有する、活性酸素消去用の経口投与組成物。An oral administration composition for eliminating active oxygen, comprising the antioxidant according to claim 3 in an amount of 0.1 to 30% by weight. 食品であることを特徴とする、請求項4に記載の経口投与組成物。The composition for oral administration according to claim 4, which is a food.
JP2003005774A 2003-01-14 2003-01-14 Polyphenols derived from walnut seeds Expired - Fee Related JP4303481B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003005774A JP4303481B2 (en) 2003-01-14 2003-01-14 Polyphenols derived from walnut seeds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003005774A JP4303481B2 (en) 2003-01-14 2003-01-14 Polyphenols derived from walnut seeds

Publications (3)

Publication Number Publication Date
JP2004217555A true JP2004217555A (en) 2004-08-05
JP2004217555A5 JP2004217555A5 (en) 2005-09-22
JP4303481B2 JP4303481B2 (en) 2009-07-29

Family

ID=32896347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003005774A Expired - Fee Related JP4303481B2 (en) 2003-01-14 2003-01-14 Polyphenols derived from walnut seeds

Country Status (1)

Country Link
JP (1) JP4303481B2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006052184A (en) * 2004-08-16 2006-02-23 Pola Chem Ind Inc Food for inhibiting oxidation stress
JP2009538871A (en) * 2006-06-02 2009-11-12 アルティントン ビジネス,エセ.エレ. Walnut isolated extract, its acquisition and use
MD4299C1 (en) * 2013-09-16 2015-03-31 Институт Генетики И Физиологии Растений Академии Наук Молдовы Process for producing antioxidant compounds from walnut kernel skin (Juglans regia L.)
MD855Z (en) * 2014-01-29 2015-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Process for preparing antioxidant compounds from kernel peel of walnut Juglans regia L.
CN106805180A (en) * 2017-01-13 2017-06-09 江南大学 A kind of method that polyphenol substance is extracted in desmoenzyme and the ultrasonically treated endotesta walnut kernel by band
WO2021002823A1 (en) * 2019-07-04 2021-01-07 Petro-Yağ Ve Ki̇myasallar Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Coolant for electronic equipment used in cryptocurrency mining

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006052184A (en) * 2004-08-16 2006-02-23 Pola Chem Ind Inc Food for inhibiting oxidation stress
JP2009538871A (en) * 2006-06-02 2009-11-12 アルティントン ビジネス,エセ.エレ. Walnut isolated extract, its acquisition and use
MD4299C1 (en) * 2013-09-16 2015-03-31 Институт Генетики И Физиологии Растений Академии Наук Молдовы Process for producing antioxidant compounds from walnut kernel skin (Juglans regia L.)
MD855Z (en) * 2014-01-29 2015-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Process for preparing antioxidant compounds from kernel peel of walnut Juglans regia L.
CN106805180A (en) * 2017-01-13 2017-06-09 江南大学 A kind of method that polyphenol substance is extracted in desmoenzyme and the ultrasonically treated endotesta walnut kernel by band
CN106805180B (en) * 2017-01-13 2020-08-07 江南大学 Method for extracting polyphenol substance from walnut kernel with inner seed coat by combining enzyme and ultrasonic treatment
WO2021002823A1 (en) * 2019-07-04 2021-01-07 Petro-Yağ Ve Ki̇myasallar Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Coolant for electronic equipment used in cryptocurrency mining

Also Published As

Publication number Publication date
JP4303481B2 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
US7829591B2 (en) Flavanone compound and uses thereof
JP4376977B2 (en) Lipase inhibitors, food additives and food
JP4205943B2 (en) Bioavailable compositions of natural and synthetic HCA
WO1999055298A1 (en) Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
CN1394139A (en) Anticancer agents
JP2004217555A (en) Polyphenol derived from walnut kernel
TWI284529B (en) A composition for lowering triglyceride
JP2005501867A (en) Novel ascorbic acid compound, its synthesis method and its use
JP7578315B1 (en) Nrf2 activator
JP4325908B2 (en) Lipolysis accelerator, skin external preparation and food and drink using the same
JP7506903B2 (en) IL-37 production promoter
JP2006052184A (en) Food for inhibiting oxidation stress
JP4034984B2 (en) Antioxidant composition
JP2000273452A (en) Antioxidant
JP2004107314A (en) Oral administration formulation for antioxidation
JP3976890B2 (en) Novel compounds or pharmacologically acceptable salts thereof and antioxidants containing them as active ingredients
JP2004269415A (en) Antioxidant
CN112972441B (en) Application of monocarbonyl curcumin compound in preparation of medicine for preventing and treating periodontitis
CA2345409C (en) Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
JP5236593B2 (en) Lipolysis accelerator
JP4509524B2 (en) High density lipoprotein cholesterol level increasing agent in blood
JP2000247880A (en) Fat decomposition-accelerating agent
JP2001097992A (en) New polyol-based compound
KR101481040B1 (en) Composition for anti-inflammation comprising [10]-gingerdione or 1-dehydro-[10]-gingerdione
KR20060121273A (en) remedy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050414

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20050414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090421

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090424

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150501

Year of fee payment: 6

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees